Boston Scientific Inc. (BSX): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Boston Scientific ( BSX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.6%. By the end of trading, Boston Scientific rose $0.17 (1.8%) to $9.41 on average volume. Throughout the day, 17,226,463 shares of Boston Scientific exchanged hands as compared to its average daily volume of 18,907,200 shares. The stock ranged in a price between $9.16-$9.42 after having opened the day at $9.25 as compared to the previous trading day's close of $9.24. Other companies within the Health Care sector that increased today were: Clovis Oncology ( CLVS), up 103.9%, Tesaro ( TSRO), up 35.1%, Chelsea Therapeutics International ( CHTP), up 22.3% and Flamel Technologies ( FLML), up 18.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $12.5 billion and is part of the health services industry. Shares are up 61.3% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Infinity Pharmaceuticals ( INFI), down 39.1%, Synta Pharmaceuticals ( SNTA), down 34.0%, Affymax ( AFFY), down 18.3% and Vermillion ( VRML), down 14.1% , were all laggards within the health care sector with Biogen Idec ( BIIB) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.